BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32627280)

  • 1. Deoxyshikonin inhibits cisplatin resistance of non-small-cell lung cancer cells by repressing Akt-mediated ABCB1 expression and function.
    Zhang S; Wang Y
    J Biochem Mol Toxicol; 2020 Oct; 34(10):e22560. PubMed ID: 32627280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
    Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
    Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
    Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
    Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer.
    Nakanishi T; Menju T; Nishikawa S; Takahashi K; Miyata R; Shikuma K; Sowa T; Imamura N; Hamaji M; Motoyama H; Hijiya K; Aoyama A; Sato T; Chen-Yoshikawa TF; Sonobe M; Date H
    Cancer Med; 2018 Feb; 7(2):408-419. PubMed ID: 29318780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
    Li A; Song J; Lai Q; Liu B; Wang H; Xu Y; Feng X; Sun X; Du Z
    Int J Exp Pathol; 2016 Dec; 97(6):412-421. PubMed ID: 27995666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathway.
    Tang XL; Yan L; Zhu L; Jiao DM; Chen J; Chen QY
    J Pharmacol Sci; 2017 Sep; 135(1):1-7. PubMed ID: 28939129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.
    Vesel M; Rapp J; Feller D; Kiss E; Jaromi L; Meggyes M; Miskei G; Duga B; Smuk G; Laszlo T; Karner I; Pongracz JE
    Respir Res; 2017 Mar; 18(1):52. PubMed ID: 28340578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
    Zhao L; Zhang W; Zhang F
    Phytother Res; 2021 Jan; 35(1):278-288. PubMed ID: 32779800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway.
    Li B; Yuan Z; Jiang J; Rao Y
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30420490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
    Feng FF; Cheng P; Sun C; Wang H; Wang W
    Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
    Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
    Hu Y; Hong Y; Xu Y; Liu P; Guo DH; Chen Y
    Apoptosis; 2014 Nov; 19(11):1627-36. PubMed ID: 25213670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.